A5060718718- Atrial Fibrillation Management and Outcomes
- Venous Thromboembolism Diagnosis and Management
- Cardiac Arrhythmias and Treatments
- Blood Pressure and Hypertension Studies
- Streptococcal Infections and Treatments
- COVID-19 Clinical Research Studies
- Long-Term Effects of COVID-19
- Antiplatelet Therapy and Cardiovascular Diseases
- Acute Ischemic Stroke Management
- Bacterial Identification and Susceptibility Testing
- Reliability and Agreement in Measurement
- COVID-19 and Mental Health
- Health Systems, Economic Evaluations, Quality of Life
- COVID-19 epidemiological studies
- Neonatal and Maternal Infections
- Antimicrobial Resistance in Staphylococcus
- Infection Control and Ventilation
- Medication Adherence and Compliance
Leiden University Medical Center
2018-2024
Whereas accumulating studies on patients with coronavirus disease 2019 (COVID-19) report high incidences of thrombotic complications, large clinically relevant thrombosis in other respiratory tract infections are lacking. How this risk COVID-19 compares to those observed hospitalized viral pneumonias such as influenza is unknown.To assess the incidence venous and arterial complications opposed that COVID-19.This was a retrospective cohort study; we used data from Statistics Netherlands...
Abstract Aims Persistence with direct oral anticoagulants (DOACs) has become a concern in non-valvular atrial fibrillation (NVAF) patients, but whether this affects prognosis is rarely studied. We investigated the persistence (OACs) and its association among nationwide cohort of NVAF patients. Methods results DOAC-naive patients who started to use DOACs for ischaemic stroke prevention between 2013 2018 were included using Dutch national statistics. OACs was determined based on presence...
Importance The temporal trend in adverse events regarding stroke prevention for nonvalvular atrial fibrillation (NVAF) the direct oral anticoagulant (DOAC) era was rarely investigated comprehensively, especially taking into account potential changes patient characteristics and anticoagulation treatment. Objective To investigate time trends characteristics, treatment, prognosis of patients with incident NVAF Netherlands. Design, Setting, Participants This retrospective cohort study assessed...
Many patients who used vitamin K antagonists (VKAs) for long-term prevention of thromboembolism are now actively switched to a direct oral anticoagulant (DOAC). Strict adherence DOAC is crucial its success. However, therapy and clinical factors that predict nonadherence currently not well studied among from VKA DOAC.
Direct oral anticoagulants (DOACs) are increasingly used for treatment and prevention of thromboembolic diseases, in fixed dose regimens. Although their safety efficacy profiles considered optimal, clinical events still occur. Given that anticoagulation is a delicate balance between clotting bleeding, it possible an optimal target spot exists where the effect achieves both lowest risk bleeding thrombosis. Other currently available (ie, vitamin K antagonists heparins) provide important clues...
Abstract Background To evaluate the association between crowding and transmission of viral respiratory infectious diseases, we investigated change in patterns influenza COVID-19 before after a mass gathering event (i.e., carnival) Netherlands. Methods Information on individual hospitalizations related to 2017/2018 epidemic were accessed from Statistics The cases stratified non-carnival carnival regions. Distributions plotted with time compared A similar investigation early outbreak was also...
The recently observed increase in invasive
Abstract Background Whereas accumulating studies on COVID-19 patients report high incidences of thrombotic complications, large clinically relevant thrombosis in with other respiratory tract infections are lacking. How this risk compares to those observed hospitalized viral pneumonias such as influenza is unknown. Objectives To assess the incidence venous and arterial complications opposed that patients. Methods Retrospective cohort study; we used data from Statistics Netherlands (study...
Major bleeding occurs in 1 to 3% of patients treated with oral anticoagulants per year. Biomarkers may help identify high-risk patients. A proposed marker for major while using is soluble thrombomodulin (sTM). Plasma was available from 16,570 the BLEEDS cohort that consisted who started treatment vitamin K antagonists between 2012 and 2014. case-cohort study performed including all a bleed (n = 326) during follow-up random sample individuals selected at baseline 652). sTM levels were...